{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:24:16Z","timestamp":1759483456491},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T00:00:00Z","timestamp":1207094400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Cinacalcet hydrochloride is a calcimimetic agent that activates the calcium\u2010sensing receptor on the surface of parathyroid cells and inhibits parathyroid hormone (PTH) secretion. To manage secondary hyperparathyroidism, cinacalcet, which lowers PTH levels without increasing serum calcium, phosphorus and calcium\u2013phosphorus product (Ca\u2003\u00d7\u2003P) levels, may provide a new potential therapy. To identify the optimal starting dose of cinacalcet for Japanese hemodialysis patients with secondary hyperparathyroidism, this double\u2010blind, placebo\u2010controlled, parallel, dose\u2010finding study was conducted. One hundred and twenty Japanese hemodialysis patients with intact PTH levels greater than or equal to 300\u2003pg\/mL were randomized into four groups: placebo, and 12.5, 25 and 50\u2003mg of cinacalcet. The treatment period was three weeks followed by a two\u2010week follow\u2010up observation period. Cinacalcet decreased serum intact PTH levels in a dose\u2010dependent manner, and also decreased serum calcium, phosphorus, Ca\u2003\u00d7\u2003P, tartrate\u2010resistant acid phosphatase and osteocalcin levels. The treatment with cinacalcet was generally well tolerated in this study. However, the incidence of treatment\u2010related adverse events, such as gastrointestinal disorders and hypocalcemia, and the rate of withdrawal from the study due to treatment\u2010related adverse events were higher in the 50\u2003mg dose group than in the other groups. On the basis of both efficacy and safety results, 25\u2003mg has been identified as the optimal starting dose of cinacalcet for Japanese hemodialysis patients with secondary hyperparathyroidism.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2008.00556.x","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T10:24:39Z","timestamp":1207131879000},"page":"117-125","source":"Crossref","is-referenced-by-count":26,"title":["Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism"],"prefix":"10.1111","volume":"12","author":[{"given":"Takashi","family":"Akiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the KRN1493 Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90459-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1081\/JDI-120022551"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908033210502"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590031187.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/hy1001.096358"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(04)01103-5"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004060512"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.170"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1053"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02088.x"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2008.00556.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2008.00556.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:00:42Z","timestamp":1697259642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2008.00556.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1744-9987.2008.00556.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2008.00556.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"type":"print","value":"1744-9979"},{"type":"electronic","value":"1744-9987"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}